HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## : ESMO-MCBS Evaluation Form - XML Representation

Active as of 2026-05-21

Raw xml | Download

    <CodeSystem xmlns="http://hl7.org/fhir">
      <id value="sact-esmo-mcbs-evaluation-form"/>
      <text>
        <status value="generated"/>
        <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem sact-esmo-mcbs-evaluation-form</b></p><a name="sact-esmo-mcbs-evaluation-form"> </a><a name="hcsact-esmo-mcbs-evaluation-form"> </a><p>This  code system <code>https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">ST-1a<a name="sact-esmo-mcbs-evaluation-form-ST-1a"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies</td></tr><tr><td style="white-space:nowrap">ST-1b<a name="sact-esmo-mcbs-evaluation-form-ST-1b"> </a></td><td>Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting</td></tr><tr><td style="white-space:nowrap">ST-2a<a name="sact-esmo-mcbs-evaluation-form-ST-2a"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style="white-space:nowrap">ST-2b<a name="sact-esmo-mcbs-evaluation-form-ST-2b"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style="white-space:nowrap">ST-2c<a name="sact-esmo-mcbs-evaluation-form-ST-2c"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style="white-space:nowrap">ST-3<a name="sact-esmo-mcbs-evaluation-form-ST-3"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr><tr><td style="white-space:nowrap">HM-1a<a name="sact-esmo-mcbs-evaluation-form-HM-1a"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies</td></tr><tr><td style="white-space:nowrap">HM-1b<a name="sact-esmo-mcbs-evaluation-form-HM-1b"> </a></td><td>Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies</td></tr><tr><td style="white-space:nowrap">HM-2a<a name="sact-esmo-mcbs-evaluation-form-HM-2a"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style="white-space:nowrap">HM-2b<a name="sact-esmo-mcbs-evaluation-form-HM-2b"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style="white-space:nowrap">HM-2c<a name="sact-esmo-mcbs-evaluation-form-HM-2c"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style="white-space:nowrap">HM-3<a name="sact-esmo-mcbs-evaluation-form-HM-3"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr></table></div>
      </text>
      <url
           value="https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form"/>
      <version value="0.1.0"/>
      <name value="EsmoMcbsEvaluationForm"/>
      <title value="ESMO-MCBS Evaluation Form"/>
      <status value="active"/>
      <date value="2026-05-21T02:29:02+00:00"/>
      <publisher value="Te Aho o Te Kahu, Cancer Control Agency"/>
      <description
                   value="The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale"/>
      <content value="complete"/>
      <count value="12"/>
      <concept>
        <code value="ST-1a"/>
        <display
                 value="Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies"/>
      </concept>
      <concept>
        <code value="ST-1b"/>
        <display
                 value="Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting"/>
      </concept>
      <concept>
        <code value="ST-2a"/>
        <display
                 value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/>
      </concept>
      <concept>
        <code value="ST-2b"/>
        <display
                 value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/>
      </concept>
      <concept>
        <code value="ST-2c"/>
        <display
                 value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/>
      </concept>
      <concept>
        <code value="ST-3"/>
        <display
                 value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/>
      </concept>
      <concept>
        <code value="HM-1a"/>
        <display
                 value="Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies"/>
      </concept>
      <concept>
        <code value="HM-1b"/>
        <display
                 value="Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies"/>
      </concept>
      <concept>
        <code value="HM-2a"/>
        <display
                 value="Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS"/>
      </concept>
      <concept>
        <code value="HM-2b"/>
        <display
                 value="Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS"/>
      </concept>
      <concept>
        <code value="HM-2c"/>
        <display
                 value="Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies"/>
      </concept>
      <concept>
        <code value="HM-3"/>
        <display
                 value="Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR"/>
      </concept>
    </CodeSystem>